Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rezvilutamide - Jiangsu Hengrui Medicine Co.

Next Previous
Drug Profile

Rezvilutamide - Jiangsu Hengrui Medicine Co.

Alternative Names: Ariane; SHR-3680

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Beijing Biote Pharmaceutical; Jiangsu Hengrui Medicine Co.; Peking University First Hospital
  • Class Alcohols; Antineoplastics; Benzonitrile; Fluorinated hydrocarbons; Imidazolidines; Ketones; Organic sulfur compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Salivary gland cancer

Most Recent Events

  • 24 Jun 2025 Jiangsu HengRui Medicine terminates a phase-II clinical trials in Prostate cancer (Metastatic disease, Monotherapy, Combination therapy, Hormone refractory, Second-line therapy or greater) in China (PO) due to the sponsor R&D strategy adjustment (NCT04102124)
  • 16 Jul 2024 Efficacy and adverse events data from the phase II trial in Prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy data from a phase III CHART trial in Prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top